IP Library Granted Patent US 10,577,611
Granted Patent B2
US 10,577,611 · App. 14/249,533 · Granted Mar 3, 2020

Multi-species polynucleotide control sequences

Inventor: Marco Alexander Van Den Berg (Poeldijk, NL)
Assignee: Centrient Pharmaceuticals Netherlands, B.V.
C12N15/63C12N15/70C12N15/75C12N15/80C12N15/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,611
App. No.
14/249,533
Granted
Mar 3, 2020
Kind
B2
Abstract

The present invention relates to polynucleotide sequences which enable a polynucleotide control sequence, such as a promoter, to direct expression in a wide range of industrially relevant species, both prokaryotes and eukaryotes. When the polynucleotide sequences of the invention are applied in combination with selection marker genes it is possible to perform selectable cloning in a laboratory host and use the same construct in the final host.

Claims (80)

1. An expression cassette comprising a gene-of-interest and a polynucleotide control sequence which directs the expression of polypeptides in at least three of the following groups of host cells: algae, fungi, yeasts, gram-positive bacteria, gram-negative bacteria, wherein the polynucleotide control sequence comprises a polynucleotide sequence of the general formula T-T-G-A-C—W-N(o)-Y 1 -A-Y 2 -A-A-T-H 1 -H 2 -N(p)-S 1 -S 2 -W-K 1 -K 2 -N(q)-H 3 -M 1 -M 2 -H 4 -A-T-G, (formula I) wherein the polynucleotide sequence is selected from any one of SEQ ID NOS: 1 to 51, wherein

N is any of the nucleotides A, C, G and T, and N(o) is 16, 17 or 18 nucleotides long;

N(p) is 22 nucleotides long;

N(q) is 2, 3, 4, 5 or 6 nucleotides long; and

each individual N in N(o), N(p), and N(q) are the same or different;

W is any of the nucleotides A and T;

Y is any of the nucleotides C and T, and Y 1 and Y 2 are the same or different;

H is any of the nucleotides A, C, and T and H 1 , H 2 , H 3 and H 4 are the same or different;

S is any of the nucleotides G and C, and S 1 and S 2 are the same or different;

K is any of the nucleotides G and T, and K 1 and K 2 are the same or different;

M is any of the nucleotides A and C, and M 1 and M 2 are the same or different;

the AG-content of N(o) is below 50%;

the A-content of N(o) is below 35%;

the AG-content within each stretch of 6 nucleotides in N(o) is below 66%;

the AG-content of N(p) is below 60%;

the AG-content within each stretch of 6 nucleotides in N(p) is below 83%;

N(o) and N(p) do not contain two consecutive G's; and

the G-content of N(q) is below 50%,

wherein the polynucleotide control sequence is either heterologous to the host cell or to the gene-of-interest coding for the polypeptide.

2. The expression cassette according to claim 1 , wherein N(o) is 17 nucleotides long; N(p) is 22 nucleotides long; and N(q) is 3 or 4 nucleotides long.

3. The expression cassette according to claim 1 , wherein the polynucleotide control sequence is selected from the group consisting of SEQ ID NO. 46 to 51.

4. The expression cassette according to claim 1 which directs the expression of polypeptides in at least four of the following genera: Escherichia, Streptomyces, Bacillus, Gluconobacter, Pseudomonas, Clostridium, Saccharomyces, Kluyveromyces, Pichia, Penicillium, Aspergillus, Mortierella, Chrysosporium, Acremonium, Trichoderma.

5. A vector comprising an expression cassette, wherein the expression cassette comprises a polynucleotide sequence and a gene-of-interest, wherein the polynucleotide control sequence comprises a polynucleotide sequence of the general formula

T-T-G-A-C-W-N(o)-Y 1 -A-Y 2 -A-A-T-H 1 -H 2 -N(p)-S 1 -S 2 -W-K 1 -K 2 -N(q)-H 3 -M 1 -M 2 -H 4 -A-T-G, (formula I) wherein the polynucleotide sequence is selected from any one of SEQ ID NOS: 1 to 51, wherein

N is any of the nucleotides A, C, G and T, and N(o) is 16, 17 or 18 nucleotides long;

N(p) is 22 nucleotides long;

N(q) is 2, 3, 4, 5 or 6 nucleotides long; and

each individual N in N(o), N(p), and N(q) are the same or different;

W is any of the nucleotides A and T;

Y is any of the nucleotides C and T, and Y 1 and Y 2 are the same or different;

H is any of the nucleotides A, C, and T and H 1 , H 2 , H 3 and H 4 are the same or different;

S is any of the nucleotides G and C, and S 1 and S 2 are the same or different;

K is any of the nucleotides G and T, and K 1 and K 2 are the same or different;

M is any of the nucleotides A and C, and M 1 and M 2 are the same or different;

the AG-content of N(o) is below 50%;

the A-content of N(o) is below 35%;

the AG-content within each stretch of 6 nucleotides in N(o) is below 66%;

the AG-content of N(p) is below 60%;

the AG-content within each stretch of 6 nucleotides in N(p) is below 83%;

N(o) and N(p) do not contain two consecutive G's; and

the G-content of N(q) is below 50%,

wherein the polynucleotide control sequence directs expression of the gene-of-interest in at least three of the following groups of host cells: algae, fungi, yeast, gram-positive bacteria, gram-negative bacteria, wherein the polynucleotide control sequence is either heterologous to the host cell or to the gene-of-interest coding for the polypeptide.

6. A host cell comprising the vector according to claim 5 .

7. A method of producing a polypeptide, a primary or secondary metabolite, an antibody or a pharmaceutical with a host cell according to claim 6 .

8. A method according to claim 7 , wherein the host cell is a cloning host, and wherein the polypeptide, primary or secondary metabolite, antibody or pharmaceutical is produced in a production host, which method comprises using the same polynucleotide control sequence in both cloning host and production host.

9. The method according to claim 8 , wherein the polynucleotide control sequence is a control sequence.

10. The method according to claim 8 , wherein the production host is of a different species than the cloning host.

11. A method for cloning a polynucleotide sequence comprising:

(a) cloning a polynucleotide sequence in front of a selectable marker gene on a vector according to the invention;

(b) transfecting a first species with the vector from step (a);

(c) obtaining clones after selection for active transcription of the selectable marker gene;

(d) isolating DNA from these clones;

(e) transfecting another species with the isolated DNA,

wherein steps (c) to (e) are repeated minimally 2 times;

wherein the polynucleotide sequence is of the general formula

T-T-G-A-C-W-N(o)-Y 1 -A-Y 2 -A-A-T-H 1 -H 2 -N(p)-S 1 -S 2 -W-K 1 -K 2 -N(q)-H 3 -M 1 -M 2 -H 4 -A-T-G, (formula I) wherein the polynucleotide sequence is selected from any one of SEQ ID NOS: 1 to 51, wherein

N is any of the nucleotides A, C, G and T, and N(o) is 16, 17 or 18 nucleotides long;

N(p) is 22 nucleotides long;

N(q) is 2, 3, 4, 5 or 6 nucleotides long; and

each individual N in N(o), N(p), and N(q) are the same or different;

W is any of the nucleotides A and T;

Y is any of the nucleotides C and T, and Y 1 and Y 2 are the same or different;

H is any of the nucleotides A, C, and T and H 1 , H 2 , H 3 and H 4 are the same or different;

S is any of the nucleotides G and C, and S 1 and S 2 are the same or different;

K is any of the nucleotides G and T, and K 1 and K 2 are the same or different;

M is any of the nucleotides A and C, and M 1 and M 2 are the same or different;

the AG-content of N(o) is below 50%;

the A-content of N(o) is below 35%;

the AG-content within each stretch of 6 nucleotides in N(o) is below 66%;

the AG-content of N(p) is below 60%;

the AG-content within each stretch of 6 nucleotides in N(p) is below 83%;

N(o) and N(p) do not contain two consecutive G's; and

the G-content of N(q) is below 50%.

12. A molecular biology kit comprising at least one reagent and a polynucleotide control sequence according to claim 1 .

13. The expression cassette according to claim 1 , wherein the polynucleotide control sequence is selected from the group consisting of SEQ ID NO. 46.

14. The expression cassette according to claim 1 , wherein the polynucleotide control sequence is selected from the group consisting of SEQ ID NO. 47.

15. The expression cassette according to claim 1 , wherein the polynucleotide control sequence is selected from the group consisting of SEQ ID NO. 48.

16. The expression cassette according to claim 1 , wherein the polynucleotide control sequence is selected from the group consisting of SEQ ID NO. 49.

17. The expression cassette according to claim 1 , wherein the polynucleotide control sequence is selected from the group consisting of SEQ ID NO. 50.

18. The expression cassette according to claim 1 , wherein the polynucleotide control sequence is selected from the group consisting of SEQ ID NO. 51.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2019
From: DSM IP ASSETS B.V.
To: CENTRIENT PHARMACEUTICALS NETHERLANDS B.V.
Reel/Frame 049750/0356 →
CHANGE OF NAME Recorded Apr 2, 2019
From: DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.
To: CENTRIENT PHARMACEUTICALS NETHERLANDS B.V.
Reel/Frame 048775/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2014
From: VAN DEN BERG, MARCO ALEXANDER
To: DSM IP ASSETS B.V.
Reel/Frame 032745/0021 →
Priority Claims (1)
EP 08158028 · Jun 11, 2008 · regional
Continuity (2)
Continuation 12997330
Related Publication 20150232860A1 · Aug 20, 2015